



Apex Medical Corp.

2020 The First Investor Conference

May 12th , 2020



Year 2019 Consolidated Income Statement

Unit: NTDK

	2019 Audited	2018 Audited	'19/'18 Var.(\$)	'19/'18 Var.(%)
Net Sales	2,036,232	2,105,748	(69,516)	-3%
Gross Profit	853,817	876,871	(23,054)	-
Gross Margin(%)	42%	42%	-	-
Operating Expenses	725,054	739,966	(14,912)	-2%
Income before Tax	128,763	150,271	(21,508)	-14%
Net Income attributed to owner of the parent company	87,921	108,413	(20,492)	-19%
Basic EPS(NT\$)	0.87	1.24	-	-



2019/12/31 Consolidated Balance Sheet(1)

Unit: NTDK

	2019/12/31 Audited	2018/12/31 Audited	Variance	
	Amount	Amount	Amount	%
Cash and cash equivalent	419,451	447,210	(27,759)	-6%
Current financial assets at fair value through profit or loss	0	138,130	(138,130)	-100%
Amortized cost financial assets	363,610	366,861	(3,251)	-1%
Accounts receivable	285,755	357,442	(71,687)	-20%
Inventories	350,817	365,620	(14,803)	-4%
Total current assets	1,485,379	1,750,185	(264,806)	-15%
Investments accounted for using equity method	211,096	203,855	7,241	4%
Property, plant and equipment	657,969	689,710	(31,741)	-5%
Right-of-use asset	101,807	0	101,807	-
Intangible Assets	432,380	431,929	451	0%
Total non-current assets	1,535,027	1,395,871	139,156	10%
Total Assets	3,020,406	3,146,056	(125,650)	-4%

Note: Only important accounts are listed in the table.



2019/12/31 Consolidated Balance Sheet(2)

Unit: NTDK


	2019/12/31 Audited	2018/12/31 Audited	Variance	
	Amount	Amount	Amount	%
Short-term debt	401,493	292,572	108,921	37%
Accounts payable and other payable*	256,320	328,662	(72,342)	-22%
Bonds payable - current	0	295,753	(295,753)	-100%
Total current liabilities	753,513	1,009,642	(256,129)	-25%
Long-term debt	153,363	105,203	48,160	46%
Lease liabilities	73,626	0	73,626	-
Total long-term liabilities	236,914	114,459	122,455	107%
Total liabilities	990,427	1,124,101	(133,674)	-12%
Total share capital	1,009,116	1,009,116	0	0%
Additional paid-in capital	345,635	345,635	0	0%
Total retained earnings	849,805	828,086	21,719	3%
Other equity	(178,568)	(163,809)	(14,759)	9%
Owners' equity attributed to the parent company	2,025,988	2,019,028	6,960	0%
Total owners' equity	2,029,979	2,021,955	8,024	0%
Total liabilities and owners' equity	3,020,406	3,146,056	(125,650)	-4%

Note: Only important accounts are listed in the table ; *the accounts payable and other payable including the amount belong to the related parties.




2019Q4YTD Sales by Department

2019Q4 YTD Act.




2018Q4 YTD Act.






2019Q4YTD Sales by Product

2019Q4 YTD Act.



2018Q4 YTD Act.





2020Q1 Consolidated Income Statement

Unit: NTDK

	2020Q1 Review	2019Q1 Review	'20/'19 Var.(\$)	'20/'19 Var.(%)
Net Sales	417,061	515,462	(98,401)	-19%
Gross Profit	169,849	223,406	(53,557)	-
Gross Margin(%)	41%	43%	-	-
Operating Expenses	161,368	180,092	(18,724)	-10%
Income before Tax	15,825	47,702	(31,877)	-67%
Net Income attributed to owner of the parent company	7,430	37,198	(29,768)	-80%
Basic EPS(NT\$)	0.07	0.37	-	-



2020/03/31 Consolidated Balance Sheet(1)

Unit: NTDK

	2020/03/31 Review	2019/03/31 Review	Variance	
	Amount	Amount	Amount	%
Cash and cash equivalent	375,518	382,951	(7,433)	-2%
Current financial assets at fair value through profit or loss	0	125,182	(125,182)	-100%
Amortized cost financial assets	328,000	446,559	(118,559)	-27%
Accounts receivable	274,332	343,400	(69,068)	-20%
Inventories	309,802	424,122	(114,320)	-27%
Total current assets	1,362,150	1,799,338	(437,188)	-24%
Investments accounted for using equity method	210,501	209,299	1,202	1%
Property, plant and equipment	642,544	688,440	(45,896)	-7%
Right-of-use assets	94,630	118,287	(23,657)	-20%
Intangible Assets	418,806	438,716	(19,910)	-5%
Other non-current assets	102,200	11,562	90,638	784%
Total non-current assets	1,516,947	1,516,065	882	0%
Total Assets	2,879,097	3,315,403	(436,306)	-13%

Note: Only important accounts are listed in the table.



2020/03/31 Consolidated Balance Sheet(2)

Unit: NTDK


	2020/03/31 Review	2019/03/31 Review	Variance	
	Amount	Amount	Amount	%
Short-term debt	312,185	256,406	55,779	22%
Accounts payable and other payable*	211,205	361,392	(150,187)	-42%
Bonds payable - current	0	297,056	(297,056)	-100%
Total current liabilities	641,569	1,040,283	(398,714)	-38%
Long-term debt	150,161	101,883	48,278	47%
Lease liabilities	67,518	88,390	(20,872)	-24%
Total long-term liabilities	227,195	199,223	27,972	14%
Total liabilities	868,764	1,239,506	(370,742)	-30%
Total share capital	1,009,116	1,009,116	0	0%
Additional paid-in capital	345,635	345,635	0	0%
Total retained earnings	857,235	865,284	(8,049)	-1%
Other equity	(205,274)	(146,857)	(58,417)	40%
Owners' equity attributed to the parent company	2,006,712	2,073,178	(66,466)	-3%
Total owners' equity	2,010,333	2,075,897	(65,564)	-3%
Total liabilities and owners' equity	2,879,097	3,315,403	(436,306)	-13%

Note: Only important accounts are listed in the table ; *the accounts payable and other payable including the amount belong to the related parties.




2020Q1 YTD Sales by Department

2020Q1 YTD Act.




2019Q1 YTD Act.






2020Q1 YTD Sales by Product

2020Q1 YTD Act.




2019Q1 YTD Act.



Recent Major Events

- ◆ Apex Medical provides CPAP ventilator solution as COVID-19 treatment alternative in May, 2020.
 1. Based on the dual guidance of the U.S. Food and Drug Administration (FDA) as well as the British Medicines and Medical Products Regulatory Agency (MHRA), CPAP has been clinically used to support COVID-19 patients with respiratory insufficiency in European countries and the United States.
 2. Despite the clinical indication of CPAP is mainly for treating sleep apnea, CPAP can still provide continuous positive airway pressure to maintain alveolar expansion, reduce the work of breathing and preserve blood oxygen level to relieve Hypoxia. For mild, moderate or recovering COVID-19 patient, this solution can be taken into account.





<http://www.apexmedicalcorp.com>

IR @apexmedicalcorp.com